what was explained to me was FDA can grant accelerated approval for CHF treatment based on its overwhelming benefits of reducing mortality and its reduction of inflammation marker around the aorta tissue. CHF and LB treatments look very positive, So goes GVHD however a jump through hoop trial will be required, however I'm optimistic we will prevail.
Ann: Half Year Report and Accounts (including Appendix 4D), page-215
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.020(1.87%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.09 | $1.056M | 959.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 19136 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 35126 | 6 |
View Market Depth
| Last trade - 10.11am 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
0.020 ( 2.32 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.09 | 362717 | ||
| Last updated 10.32am 03/05/2024 ? | |||||
| MSB (ASX) Chart |